Primary Children's Hospital

Running trials

• Recruiting

  A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information

  NCT07621614· Phase 2· Source

• Recruiting

  A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

  NCT07466316· Phase 3· Source

• Recruiting

  Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

  NCT07194044· Phase 1· Source

• Recruiting

  Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

  NCT06579469· Source

• Active, not recruiting

  A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

  NCT07107945· Phase 3· Source

• Active, not recruiting

  A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

  NCT06872125· Phase 3· Source

• Recruiting

  A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT06124157· Phase 2· Source

• Recruiting

  A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

  NCT06401330· Phase 3· Source

• Recruiting

  Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

  NCT06647953· Phase 3· Source

• Enrolling by invitation

  Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

  NCT06823115· Source

• Active, not recruiting

  A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

  NCT06255028· Phase 1· Source

• Recruiting

  Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

  NCT06541262· Phase 1/2· Source

• Recruiting

  A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

  NCT06368817· Phase 2· Source

• Recruiting

  A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

  NCT05849662· Phase 1/2· Source

• Recruiting

  A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

  NCT05711667· Phase 3· Source

• Recruiting

  Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  NCT06172296· Phase 3· Source

• Recruiting

  Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer

  NCT05958316· Source

• Recruiting

  A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

  NCT06173518· Phase 1· Source

• Recruiting

  A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

  NCT05675410· Phase 3· Source

• Active, not recruiting

  Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

  NCT05457556· Phase 3· Source

• Recruiting

  Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

  NCT05535166· Phase 2· Source

• Recruiting

  Duchenne Electronic Health Record Study

  NCT07609394· Source

• Active, not recruiting

  Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

  NCT05286801· Phase 1/2· Source

• Enrolling by invitation

  EXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study

  NCT05610787· Source

• Recruiting

  A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

  NCT05634369· Phase 1/2· Source

• Recruiting

  Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  NCT05476770· Phase 1· Source

• Active, not recruiting

  Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  NCT05183035· Phase 3· Source

• Recruiting

  A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)

  NCT05201144· Phase 2· Source

• Recruiting

  Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

  NCT05304585· Phase 3· Source

• Recruiting

  A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

  NCT05135975· Phase 2· Source

• Active, not recruiting

  A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

  NCT05099003· Phase 1/2· Source

• Active, not recruiting

  A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor

  NCT04939597· Phase 3· Source

• Recruiting

  The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  NCT04726241· Phase 1/2· Source

• Recruiting

  Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

  NCT05235165· Phase 3· Source

• Recruiting

  Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  NCT05082519· Phase 2· Source

• Recruiting

  CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  NCT04870944· Phase 1/2· Source

• Active, not recruiting

  Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

  NCT04759586· Phase 3· Source

• Active, not recruiting

  A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

  NCT04994132· Phase 3· Source

• Recruiting

  A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

  NCT04684368· Phase 2· Source

• Active, not recruiting

  Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04320888· Phase 2· Source

• Recruiting

  Childhood Cancer Predisposition Study (CCPS)

  NCT04511806· Source

• Recruiting

  VNS Prospective Neuromodulation of Immune and Gastrointestinal Systems

  NCT03953768· Source

• Active, not recruiting

  Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

  NCT04385277· Phase 2· Source

• Recruiting

  A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  NCT04546399· Phase 2· Source

• Recruiting

  A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  NCT04322318· Phase 2· Source

• Active, not recruiting

  Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04284774· Phase 2· Source

• Active, not recruiting

  A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

  NCT04195399· Phase 2· Source

• Recruiting

  A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  NCT04293562· Phase 3· Source

• Active, not recruiting

  Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

  NCT04195555· Phase 2· Source

• Active, not recruiting

  Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

  NCT03919071· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers34 recruiting
• Acute lymphoblastic leukaemia8 recruiting
• Sarcoma7 recruiting
• Neuroblastoma4 recruiting
• Acute myeloid leukemia3 recruiting
• Kidney cancer3 recruiting
• High blood pressure2 recruiting
• Hodgkin lymphoma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Epilepsy1 recruiting
• Heart failure1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Obesity1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Sjögren's disease1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.

  NCT05689164· Phase 3· Source

• Recruiting

  A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

  NCT04782258· Phase 3· Source

• Recruiting

  A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

  NCT05504291· Phase 2· Source

• Terminated

  Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

  NCT05429372· Phase 2· Source

• Terminated

  A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

  NCT05163314· Phase 3· Source

• Completed

  A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

  NCT04938427· Phase 3· Source

• Completed

  An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome

  NCT04442295· Phase 1/2· Source

• Completed

  Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant

  NCT04380311· Source

• Completed

  Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

  NCT03786783· Phase 2· Source

• Completed

  Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

  NCT03790332· Phase 1/2· Source

• Completed

  Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

  NCT03678753· Phase 3· Source

• Completed

  Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

  NCT03526250· Phase 2· Source

• Terminated

  A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy

  NCT03362502· Phase 1· Source

• Completed

  Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213678· Phase 2· Source

• Completed

  Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213665· Phase 2· Source

• Completed

  Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

  NCT03220035· Phase 2· Source

• Completed

  Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213691· Phase 2· Source

• Completed

  Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

  NCT03233204· Phase 2· Source

• Completed

  Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  NCT02828358· Phase 2· Source

• Completed

  A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

  NCT02927769· Phase 2· Source

• Completed

  Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy

  NCT02879643· Phase 1· Source

• Completed

  A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

  NCT02723994· Phase 2· Source

• Completed

  Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

  NCT02470091· Phase 2· Source

• Completed

  A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

  NCT02615691· Phase 3· Source

• Completed

  Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

  NCT02180867· Phase 2/3· Source

• Completed

  Molecular-Guided Therapy for Childhood Cancer

  NCT02162732· Source

• Completed

  Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

  NCT01979536· Phase 2· Source

• Completed

  Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer

  NCT01802567· Source

• Completed

  Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

  NCT01553149· Phase 2· Source

• Completed

  Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

  NCT01602666· Phase 2· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

  NCT02883049· Phase 3· Source

• Completed

  Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

  NCT01175356· Phase 1· Source

• Completed

  Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  NCT01371981· Phase 3· Source

• Completed

  Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma

  NCT01236560· Phase 2/3· Source

• Completed

  Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

  NCT01231906· Phase 3· Source

• Completed

  Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

  NCT01190930· Phase 3· Source

• Completed

  Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

  NCT01096368· Phase 3· Source

• Completed

  Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

  NCT00980460· Phase 3· Source

• Completed

  Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

  NCT00945009· Phase 3· Source

• Completed

  Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

  NCT00653068· Phase 3· Source

• Completed

  Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

  NCT00557193· Phase 3· Source

• Completed

  Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

  NCT00336024· Phase 3· Source

• Completed

  Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

  NCT00392327· Phase 3· Source

• Completed

  Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

  NCT00379340· Phase 3· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

  NCT00408005· Phase 3· Source

• Completed

  Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

  NCT00352534· Phase 3· Source

• Completed

  Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

  NCT00107198· Phase 2· Source

• Completed

  Study of Kidney Tumors in Younger Patients

  NCT00898365· Source

• Completed

  Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

  NCT00085735· Phase 3· Source

• Completed

  Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

  NCT00082745· Source

Trial sites

• Primary Children's Hospital134 trials
• Primary Children's Hospital/University of Utah1 trial
• University of Utah, Primary Children's Hospital5 trials
• University of Utah - Primary Children's Hospital - PPDS2 trials